Stock Ratings / Health Care / ENTX / options

ETRA (48) VALN (58) SRZN (27) RGNX (39) ⌘ Pro Terminal →

Entera Bio Ltd. (ENTX) Options Positioning, Max Pain & Unusual Sweeps

$3.12 +0.65% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.12

Entera Bio Ltd. (ENTX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $542.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.12 (-0.07%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ENTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY ENTX SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (25% of score)

FRED Regime × Technicals: 67% of 52W Range • RSI-14 at 63.6 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.66+0.8% Next Q

Q2 (-2Q)

Grade E$2.68+9% Next Q

Q3 (-1Q)

Grade E$2.92+6.8% Next Q

Current

Grade D-$3.12-7.4% Hist 90D α

Trajectory: E (32) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ENTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ENTX currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.90) and Max Pain ($3.28) forces dealer call-delta covering toward $4.41.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ENTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ENTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ENTX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ENTX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ENTX)

✓Walkthrough of ENTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ENTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +162.18%⚡ TESTING RESISTANCE

2026-10-30O $3.06H $3.24L $2.95C $3.12VOL 291.7K

RES: $3.20SUP: $2.36SMA50: $2.90SMA200: $1.91

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ENTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ENTX Butterfly Map → + Track ENTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ENTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ENTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ENTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ENTX)

Health Care Rank #636 of 1016 ⚔️ ETRA vs ENTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ENTX vs. ETRA, VALN, SRZN, RGNX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Entera Bio Ltd. (ENTX) ranks #636 by composite RQD confidence (40/100, grade D-) and #433 by equity capitalization ($542.6M). Within this direct 5-issuer industry benchmark cohort, ENTX leads on earnings valuation at N/A trailing P/E, while ENTX leads on capital efficiency and profitability with -33.6% ROIC and 0.0% gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with ENTX at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ENTX ACTIVE Entera Bio Ltd.	D-	40/100	—	0.0%	-33.6%	+0.65%	$542.6M	Benchmark Subject
ETRA Electra Therapeutics Inc.	D	48/100	—	—	—	-3.79%	$542.3M	/etra-vs-entx →
VALN Valneva SE	D+	58/100	—	—	—	-0.52%	$541.8M	/valn-vs-entx →
SRZN Surrozen Inc.	E	27/100	—	—	-35.0%	-2.93%	$524.4M	/srzn-vs-entx →
RGNX REGENXBIO Inc.	D-	39/100	—	—	-35.0%	+2.35%	$489.2M	/rgnx-vs-entx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001638097

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Entera Bio Ltd. (ENTX) reported GAAP revenue of $42.0K (-76.8% vs. FY2024 revenue of $181.0K ) , GAAP net income of -$11.4M, operating cash flow of -$7.4M, and free cash flow of -$7.5M (-9.6% YoY). On the balance sheet, ENTX closed FY2025 with $16.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$42.0K	-$11.4M	-$7.4M	-$7.5M	$16.0M	—
FY2024 (FY)	2024-12-31	$181.0K	-$9.5M	-$6.8M	-$6.8M	$9.4M	—
FY2023 (FY)	2023-12-31	$0	-$8.9M	-$7.3M	-$7.3M	—	—

3. ENTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ENTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Entera Bio Ltd. (NASDAQ: ENTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.12 (+0.65% 1D, market cap $542.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ENTX ranks #636 in composite RQD confidence.

How does ENTX compare to ETRA and VALN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ENTX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 0.0%, and ROIC of -33.6%. By comparison, ETRA (Electra Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $542.3M) and VALN (Valneva SE) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $541.8M). Among the 5-stock peer group, ENTX leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ENTX?

Per ENTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001638097), Entera Bio Ltd. generated $42.0K in revenue (-76.8% YoY), -$11.4M in net income, and -$7.5M in free cash flow against $16.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ENTX trading relative to its 50-day, 200-day, and 52-week technical levels?

ENTX last traded at $3.12 (+0.65% on volume of 140,956 shares), positioning the stock +7.59% above its 50-day simple moving average ($2.90) and +63.35% above its 200-day simple moving average ($1.91). Across its 52-week range of $0.91 to $4.20, ENTX sits at the 67.2% percentile with a 14-day RSI of 63.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.73 to $3.51).

ENTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ENTX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ENTX.

Direct Sub-Reports: ENTX RQD Cockpit ENTX 12M Forecast ENTX Earnings & Move ENTX Dividends & DRIP ENTX Insiders & 13F ENTX Whale Options ENTX Profit Sankey ENTX News & Why